徐建青博士国家性病艾滋病预防控制中心副研究员,美国马.pdfVIP

Jianqing Xu, M.D PhD, Professor at Fudan University。 Dr. Jianqing Xu is a member of International Society of Analytical Cytology (ISAC), a member of Microbiology and Immunology Council in China. He has been working on HIV vaccine development and HIV immunology for over a decade and established a HIV-specific T-cell assay base on inactivated HIV particles, developed a therapeutic vaccine named as DermaVir which is under the clinical testing both in Europe and USA. In addition, he proposed a new vaccine strategy “Sequential Immunization with Heterologous Immunogens” which is capable of preferentially stimulating immunity against HIV conserved subdominant epitopes, such a strategy may be also applicable for HCV and influenza. Currently, his team focuses on novel strategies to develop effective vaccines against HIV-1 and influenza and to explore the immune protective mechanism in HIV-1 infection. Selected Publications （*correspondence author） 1. Wan Y, Xu J*. HIV/AIDS vaccine development: Are we walking out from the darkness? Chinese Medical Journal (Engl), 2010，123: 3489-94. 2. Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP(+)) mimicking naturally occurring HIV. Vaccine. 2010 Nov 23. 3. MENG Zhe-feng, ZHANG Xiao-yan, XIN Ruo-lei, XING Hui, HE Xiang, Xu J* and SHAO Yi-ming. A new approach for sequencing virion genome of Chinese HIV-1 strains subtype B and BC from plasma. Chin Med J [IF: 0.952] 2011, 124(2):304-308. 4. Yao X, Wang X, Zhao C, Sun S, Meng Z, Zhang J, Xu J, Xie Y, Yuan Z and Wen Y. Transcriptional Analysis of Immune-Related Genes in Dendritic Cells From Hepatitis B Surface Antigen (HBsAg)-Positive